Developing medicines is a minefield that Tranzyme Pharma has navigated well so far. But the Durham company is about to embark on one of its trickiest missions.
Posts Tagged ‘diabetes’
RTP Wrapup 2/26
Friday, February 26, 2010, 12:22 am No Comments | Post a CommentA Senate committee report blasts GlaxoSmithKline for being more concerned about the sales of Avandia than about possible serious cardiovascular risks associated with the blockbuster diabetes pill. Also, two Research Triangle area companies developing new drugs sign deals.
Digging for the roots of diabetes
Wednesday, December 9, 2009, 7:58 pm No Comments | Post a CommentEvery year, the number of Americans with diabetes rises by about 1 million and genetic risk factors alone can be blamed for only a small portion of the cases. The 30 to 35 known diabetes genes, as researchers have dubbed them, account for only about 10 percent of the risk that a brother or sister of a diabetic will also develop the disease.
Dr. Ronald Kahn
To better understand the other 90 percent, said Dr. Ronald Kahn, a Harvard University medical professor and vice chairman of the Joslin Diabetes Center, “we have to look at the environment.” Read more…
RTP Weekahead 12/7
Sunday, December 6, 2009, 11:36 pm No Comments | Post a CommentEvents taking place the week of Dec. 7 in the Research Triangle area that are open to the public:
Read more…
Next: A crucial decision
Thursday, September 3, 2009, 8:23 am 1 Comment | Post a CommentThis is the last part. Continued from part 2.
Getting a ghrelin drug to market
Thursday, September 3, 2009, 8:20 am No Comments | Post a CommentThis is the second part of three. Continued from part 1.
Work on promising ghrelin medicines has gotten to a critical stage a decade after Japanese researchers discovered the hormone that stimulates hunger and is linked to insulin production.
Ghrelin: A new hormone is found
Thursday, September 3, 2009, 8:15 am No Comments | Post a CommentINTRODUCTION
Tranzyme Pharma is one of dozens of drug development companies in North Carolina’s Research Triangle area, a biotech hot spot that is ranked third in the nation by number of companies. The Durham company has diligently advanced therapies based on a hormone that was discovered a decade ago, a technology also used by two rivals. Now, Tranzyme’s Board of Directors has to decide how to pay for the final development step and get its drugs to market: Go public, sell the company or go back to its investors hat in hand one more time.
This is the first part of three.
Next: A crucial decision
Tuesday, July 28, 2009, 9:14 am No Comments | Post a CommentThis is the last part. Continued from part 2.
Developing medicines is a minefield that Tranzyme Pharma has navigated well so far. But the Durham company is about to embark on one of its trickiest missions.
Getting a ghrelin drug to market
Tuesday, July 14, 2009, 11:38 am No Comments | Post a CommentThis is the second part of three. Continued from part 1.
Work on promising ghrelin medicines has gotten to a critical stage a decade after Japanese researchers discovered the hormone that stimulates hunger and is linked to insulin production.
Ghrelin: A new hormone is found
Monday, July 6, 2009, 9:24 am No Comments | Post a CommentINTRODUCTION
Tranzyme Pharma is one of dozens of drug development companies in North Carolina’s Research Triangle area, a biotech hot spot that is ranked third in the nation by number of companies. The Durham company has diligently advanced therapies based on a hormone that was discovered a decade ago, a technology also used by two rivals. Now, Tranzyme’s Board of Directors has to decide how to pay for the final development step and get its drugs to market: Go public, sell the company or go back to its investors hat in hand one more time.
This is the first part of three.
